We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Issues Split-Decision for Gilead’s HIV Prevention Drug
FDA Panel Issues Split-Decision for Gilead’s HIV Prevention Drug
The FDA’s Antimicrobial Drugs Advisory Committee voted Wednesday to recommend Gilead Sciences’ supplemental NDA for Descovy (emtricitabine and tenofovir alafenamide ) for prevention of HIV-1 infections in men and transgender women — but shot down the drug for use in cisgender women.